ESMO Congress 2026

The evidence base for BRAF as a therapeutic target is well established: a 2002 pan-cancer screen detected BRAF somatic missense mutations in 66% of malignant melanomas, with a single V599E substitution accounting for 80%, and the mutant protein showing elevated kinase activity and transforming capacity^[1]. The clinical position of targeting this pathway was established by the phase 3 trial of vemurafenib — in 675 previously untreated metastatic melanoma patients with BRAF V600E, 6-month overall survival was 84% vs 64%, with a relative reduction of 63% in the risk of death^[2]. The immunotherapy line stands equally firm: in a phase 3 trial of previously untreated metastatic melanoma without BRAF mutation, nivolumab vs dacarbazine yielded 1-year overall survival of 72.9% vs 42.1%^[4], nivolumab plus ipilimumab has reported 3-year overall survival with randomization stratified by BRAF mutation status^[6]; and immunogenomic analysis showed BRAF mutations correlate with higher leukocyte levels^[3], providing the backdrop for combining targeted and immune approaches.

At this ESMO26 there are two BRAF-related readouts. The main one is the melanoma oral session: in first-line BRAF V600 melanoma, upfront BRAF/MEK inhibitors plus anti–PD-1 delivered what was described as striking disease control, with anti–PD-1 monotherapy as the comparator, presented by Dirk Schadendorf, and previewed by Pfizer. The other is a meta-analysis on the NSCLC side: conducted with the OncBrothers, it included 589 patients with BRAF V600E-mutant aNSCLC, comparing first-line BRAF/MEK inhibitors with ICI-based regimens — response rates were 61% vs 48%, with no differences in PFS or OS.

Relative to existing knowledge, the melanoma readout pushes two treatment classes that each already have phase 3 evidence^[2][4] into first-line combination use, with the real controversy being the comparator choice — the phase 3 evidence for first-line nivolumab monotherapy came from patients without BRAF mutation^[4], and whether today's first-line question should be benchmarked against immunotherapy combinations^[6] is exactly what the on-site critique that 'the comparator is the real question' implies. The NSCLC meta-analysis suggests that first-line BRAF/MEK inhibitors buy a higher response rate without translating into PFS or OS benefit, serving sequencing strategy rather than a replacement conclusion.

As for limitations: the field posts disclose no specific efficacy numbers or definition of 'disease control' for the melanoma trial, with full data awaiting formal presentation; the meta-analysis is a cross-trial indirect comparison, with details such as population distribution and follow-up duration not disclosed, so conclusions should await formal publication.